Palmitoyl Tetrapeptide-7: The Anti-Inflammaging Component of Matrixyl 3000
Palmitoyl Tetrapeptide-7 (CAS 221227-05-0) is a lipopeptide specifically designed to counteract inflammaging, the chronic low-grade inflammation that accelerates visible skin aging. With a molecular weight of 573.72 g/mol, this palmitoylated tetrapeptide inhibits interleukin-6 (IL-6) release from keratinocytes, directly addressing one of the root biochemical drivers of premature skin aging. It forms the anti-inflammatory half of the Matrixyl 3000 complex alongside Palmitoyl Tripeptide-1.
Mechanism of Action: IL-6 Suppression and Inflammaging Control
Chronic ultraviolet exposure, pollution, and intrinsic aging processes trigger persistent IL-6 secretion from epidermal keratinocytes. This pro-inflammatory cytokine cascade degrades collagen through matrix metalloproteinase (MMP) upregulation, impairs fibroblast function, and disrupts the organized architecture of the dermal extracellular matrix. Over months and years, this subclinical inflammation manifests as fine lines, loss of firmness, and uneven skin texture.
Palmitoyl Tetrapeptide-7 interrupts this cycle at the cytokine level. By suppressing IL-6 release from stressed keratinocytes, the peptide reduces downstream MMP activation and preserves existing collagen structures. The palmitoyl (C16) fatty acid conjugation serves a dual purpose: it enables penetration through the lipid-rich stratum corneum and localizes the peptide within the epidermal compartment where keratinocyte-driven inflammation originates.
Efficacy Data: In Vitro and Clinical Results
In UV-stressed keratinocyte cultures, Palmitoyl Tetrapeptide-7 at 50 ppm reduced IL-6 secretion by 45% compared to untreated controls. This level of cytokine suppression is sufficient to meaningfully reduce MMP-mediated collagen degradation in the surrounding tissue environment. The anti-inflammatory effect is selective, targeting the IL-6 pathway without broad immunosuppression.
The clinical validation of Palmitoyl Tetrapeptide-7 comes primarily through its combination with Palmitoyl Tripeptide-1 in the Matrixyl 3000 system. In a controlled clinical study with 35 participants, twice-daily application of the combined peptides produced a 44% reduction in wrinkle volume after 2 months of treatment. This dual-action approach, simultaneous collagen stimulation and inflammation control, addresses aging from both the constructive and protective sides of skin biology.
The Synergy Principle: Why Matrixyl 3000 Outperforms Single Peptides
Collagen synthesis alone cannot fully reverse visible aging if the inflammatory environment continues to degrade newly formed matrix proteins. Conversely, anti-inflammatory intervention alone preserves existing structures but does not rebuild depleted collagen reserves. The Matrixyl 3000 pairing solves both problems simultaneously: Palmitoyl Tripeptide-1 drives new collagen production through TGF-beta activation, while Palmitoyl Tetrapeptide-7 protects both new and existing collagen by suppressing IL-6-mediated MMP activity. This is why the combination consistently outperforms either peptide used in isolation.
Formulation Parameters
| Parameter | Specification |
|---|---|
| INCI Name | Palmitoyl Tetrapeptide-7 |
| CAS Number | 221227-05-0 |
| Molecular Weight | 573.72 g/mol |
| Recommended Use Level | 10-1000 ppm (pure peptide) |
| Optimal pH Range | 5.0 – 7.0 |
| Addition Temperature | Below 45 degrees C (cool-down phase) |
| Solubility | Oil-soluble (palmitoyl chain – add to oil phase) |
Processing and Stability Notes
Like all palmitoylated peptides, Palmitoyl Tetrapeptide-7 is oil-soluble and should be incorporated into the oil phase of emulsions or pre-dissolved in a lipophilic carrier before addition. Maintain processing temperatures below 45 degrees C during peptide addition to preserve the amide bonds. The pH window of 5.0-7.0 provides excellent peptide stability and aligns with the physiological skin pH range.
When formulating Matrixyl 3000 systems, combine both Palmitoyl Tetrapeptide-7 and Palmitoyl Tripeptide-1 in the same oil-phase premix. Their similar solubility profiles and identical processing windows simplify co-formulation. Both peptides can be dissolved together in a shared lipophilic carrier before incorporation into the main batch.
Sourcing from TCS NEXUS S.L.
TCS NEXUS S.L. in Valencia, Spain, supplies Palmitoyl Tetrapeptide-7 with comprehensive analytical documentation: HPLC purity analysis, electrospray mass spectrometry confirmation, amino acid composition, and certificate of analysis. European warehouse stock enables rapid fulfillment across the EU and UK markets. Our peptide chemists provide formulation guidance for Matrixyl 3000-type systems and custom anti-aging peptide combinations.
Frequently Asked Questions
What does inflammaging mean in cosmetic science?
Inflammaging refers to chronic, low-grade inflammation driven by UV exposure, pollution, and intrinsic cellular aging. Unlike acute inflammation, it produces no visible redness but steadily degrades collagen and elastin through persistent MMP activation. Palmitoyl Tetrapeptide-7 specifically targets this process by suppressing IL-6 cytokine release.
Is Palmitoyl Tetrapeptide-7 the same as Rigin?
Rigin is an older trade name associated with a similar tetrapeptide sequence. Palmitoyl Tetrapeptide-7 is the current INCI-recognized name for the palmitoylated version used in modern Matrixyl 3000 formulations. Always verify CAS 221227-05-0 when sourcing to confirm identity.
Can Palmitoyl Tetrapeptide-7 be combined with retinol?
Yes. Since retinol can trigger inflammatory responses in skin, Palmitoyl Tetrapeptide-7 may help mitigate retinol-induced irritation through its IL-6 suppression mechanism. pH compatibility should be verified, as retinol formulations sometimes operate below pH 5.0.
Further reading: See also: Cosmetic Peptides Technical Guide
Technical Support and Samples
Request COA documents, sample availability, or support for custom synthesis.
Frequently Asked Questions
Do you provide COA documents for Palmitoyl Tetrapeptide-7 | Matrixyl 3000 EU Supplier?
Yes. Each lot can be supplied with a Certificate of Analysis, HPLC purity data, and relevant quality-control results for technical review.
Are samples available for Palmitoyl Tetrapeptide-7 | Matrixyl 3000 EU Supplier?
Yes. Sample availability can be confirmed for formulation screening and internal evaluation before a commercial order is placed.
What is the delivery lead time for Palmitoyl Tetrapeptide-7 | Matrixyl 3000 EU Supplier?
For stocked material in Valencia, EU delivery is typically 5 to 7 business days. Final timing depends on destination and requested volume.
Do you also support custom synthesis and technical inquiries?
Yes. The team can help with custom synthesis, raw-material selection, technical documentation, and supply planning.